We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics

108 hedge funds and large institutions have $300M invested in Karyopharm Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $4.08M | Put options by funds: $1.3M

100% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 21

0.03% less ownership

Funds ownership: 5.65%5.61% (-0.03%)

6% less funds holding

Funds holding: 115108 (-7)

27% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 26

38% less capital invested

Capital invested by funds: $482M → $300M (-$182M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
108
Holders Change
-7
Holders Change %
-6.09%
% of All Funds
2.34%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
19
Increased
42
Reduced
21
Closed
26
Calls
$4.08M
Puts
$1.3M
Net Calls
+$2.78M
Net Calls Change
+$3.12M

KPTI Hedge Fund Activity: Q1 2019 in Review

108 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2019, worth a combined $300M — down 38% from $482M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of KPTI and 19 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 42 added.

The largest buyer was Millennium Management, adding an estimated $16.8M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $14.4M sold.

  • 108 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2019, down from 115 in Q4 2018.
  • Funds reported $300M of Karyopharm Therapeutics stock for Q1 2019, down 38% quarter-over-quarter.
  • 19 funds opened new Karyopharm Therapeutics positions in Q1 2019 and 26 closed out, a net change of -7 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2019 was Millennium Management, an estimated $16.8M added.
  • The largest Karyopharm Therapeutics seller in Q1 2019 was Point72 Asset Management, an estimated $14.4M sold.

Based on aggregated 13F filings for Q1 2019.